Glandular odontogenic cyst is a rare and recently recognized type of developmental odontogenic cyst. Being odontogenic in origin, because of the pluripotentiality of the odontogenic epithelium it can show glandular or salivary features. A 46 year old female patient was referred to the Oral and Maxillofacial Surgery department with chief complaint of painless swelling in the right anterior region of maxilla, radiographically associated with teeth 12, 13. Mucosa over the swelling was slightly bluish in colour and no associated palatal swelling was seen. No incidence of trauma was reported and involved teeth were not mobile. Although we have many differential diagnoses, our working diagnosis was a periapical cyst, so conventional treatment of root canal treatment, cyst enucleation, and apicoectomy was planned. Here we present a case which was initially misdiagnosed and mismanaged but on subsequent histopathologic examination revealed the final diagnosis.
1 July 2020 in National Journal of Maxillofacial Surgery
In most of the cystic lesions appearing in the oral cavity, proper diagnosis and treatment remains a challenge. As glandular odontogenic cyst (GOC) is a rare type of developmental odontogenic cyst, it was not included in our differential diagnosis. The report of GOC was quite surprising as it was rare and never came in this discussion. A 25-year-old male patient was reported to our center with a chief complaint of painless swelling in the right anterior region of the maxilla. The swelling was oval shaped and diffuse extending from the distal aspect of 11 to the mesial aspect of 14 and superiorly extending into the sulcus. Working diagnosis was a periapical cyst, so conventional treatment of root canal treatment, cyst enucleation, and apicoectomy was done. This article presents a rare case which was primarily misdiagnosed and treated and has been subsequently revealed histopathologically as a rare clinicopathological entity.
All patients with the same TNM stage are treated according to the current algorithms for the clinical treatment of patients with head and neck squamous cell carcinoma (HNSCC). Patient outcomes can be considerably improved by choosing a therapy based on a patient's unique distinctions in the genetic and biological properties of the tumour. Rapid technology advancements that enable thorough molecular characterisation of malignancies quickly and affordably have improved our understanding of the molecular pathways involved in tumour transformation and HNSCC disease development. Mining genetic data to enhance tumour staging, prognosis, and personalised therapy choices for HNSCC patients has not yet become standard practice despite noteworthy accomplishments in other tumour forms. We analyse and summarise both old and new data on predictive biomarkers for HNSCC in this review, intending to potentially enhance clinical patient care shortly.